site stats

Atara tab-cel

WebIn 2024, Atara and Pierre Fabre entered a strategic collaboration to commercialize tabelecleucel (tab-cel ® )* in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV) positive cancers. Atara retained full rights to tab-cel ® in other major markets, including North America, Asia Pacific, and Latin America. WebJun 4, 2024 · SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its …

A Study to Evaluate Tabelecleucel in Participants With …

WebJan 10, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... WebJun 7, 2024 · Atara is applying this one platform to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV + PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next ... l-4959 bascharage https://sienapassioneefollia.com

Atara Biotherapeutics Announces Positive Results from Pivotal …

WebTab-cel®, Atara's most advanced T-cell immunotherapy in development, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated … WebDec 14, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... Web© 2024 Atara Biotherapeutics, Inc. All rights reserved. progressive stocks with dividends

Atara Biotherapeutics, Inc. Reports Inducement Grants Under …

Category:Atara Biotherapeutics Announces Positive Results from Pivotal …

Tags:Atara tab-cel

Atara tab-cel

Atara Biotherapeutics, Inc. Reports Inducement Grants Under …

WebWe have advanced, in-house process science and scale-up technology which enables a highly efficient manufacturing approach and distribution process and is designed to rapidly deliver product and enable a reliable, biologics-like cost of goods for patients. Cryogenic storage provides extensive shelf life for T cells and optimizes inventory ... WebSets up, monitors, samples, and analyzes cell culture processes. Assists in maintaining laboratory, monitoring lab inventory, and ordering supplies. Documents laboratory procedures and experiments with great attention to detail in laboratory notebooks. Provides support for the development of manufacturing processes for cell therapy products.

Atara tab-cel

Did you know?

WebOct 14, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... WebMar 31, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant ...

WebTrial Description. 3. NCT03394365. Tabelecleucel for Solid Organ Transplant (SOT) subjects after failure of rituximab or rituximab and chemotherapy, and in Hematopoietic Cell Transplant (HCT) subjects after failure of rituximab (ALLELE) 2. NCT04554914. A Study to Evaluate Tabelecleucel in Participants With Epstein-Barr Virus-associated Diseases. WebDec 14, 2024 · Tabelecleucel (tab‐cel) is an off-the-shelf, allogeneic T-cell immunotherapy in development for the treatment of Epstein-Barr virus-positive post-transplant …

WebDec 14, 2024 · Atara Biotherapeutics Inc 2.71. 0.00 (0.0%) Upgrade to Real-Time Share Price; Chart; Level 2; News; Trades; Options New; Financials; Historical; Buy. Sell. Share Name Share Symbol Market Type; Atara Biotherapeutics Inc: NASDAQ:ATRA: NASDAQ: Common Stock Price Change % Change Share Price Bid Price Offer Price ... WebDec 19, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein …

WebApr 14, 2024 · Summary. Atara Biotherapeutics recently updated that its lead program, tab-cel, remains on track despite the COVID-19 pandemic. Tab-cel is the most advanced allogeneic T-cell immunotherapy and, in ...

WebJan 4, 2024 · Atara is applying this one platform to create a robust pipeline including: tab-cel ® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV + PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation ... progressive stock yahoo financeWebSep 18, 2024 · Tabelecleucel will be administered in cycles lasting for 35 days. During each cycle, participants will receive tabelecleucel at a dose of 2 x 10^6 cells/kg intravenously … progressive stock price yahooWebJul 5, 2024 · Poised to capture the global market, Atara will file a conditional approval for tab-cel in the EU with the initial Phase 3 results in 2024. After the application is accepted by the EMA, Atara will ... progressive strawberry slicer